A preliminary comparison of the efficacy and tolerability of botulinum toxin serotypes A and B in the treatment of myofascial pain syndrome: A retrospective, open-label chart review

Clinical Therapeutics

Volumn 25, Issue 8, 2003, Pages 2268-2278

  Lang, Amy M ^a,b  

^a EMORY UNIVERSITY HOSPITAL   (United States)

^b orthoREHAB Plus   (United States)

Author keywords

Botulinum toxin type A; Botulinum toxin type B; Myofascial pain syndrome; Neurotoxin; Serotype

Indexed keywords

BOTULINUM TOXIN A; BOTULINUM TOXIN B;

ADULT; ANALGESIA; DISEASE SEVERITY; DRUG EFFICACY; DRUG TOLERABILITY; DRY EYE; FEMALE; FLU LIKE SYNDROME; HUMAN; INJECTION PAIN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MUSCLE WEAKNESS; MYOFASCIAL PAIN; NECK MUSCLE; OPEN STUDY; RETROSPECTIVE STUDY; REVIEW; SEROTYPE; VISUAL ANALOG SCALE; VISUAL DISORDER; XEROSTOMIA;

EID: 0041384512     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(03)80218-7     Document Type: Article

References (28)

1. Borg-Stein J, Simons DG. Focused review: Myofascial pain. Arch Phys Med Rehabil. 2002;83(Suppl 1):S40-S47, S48-S49.
2. Gerwin RD. The management of myofascial pain syndromes. J Musculoskeletal Pain. 1993;1:83-94.
3. Gam AN, Warming S, Larsen LH, et al. Treatment of myofascial trigger-points with ultrasound combined with massage and exercise - a randomised controlled trial. Pain. 1998;77:73-79.
4. Esposito CJ, Veal SJ, Farman AG. Alleviation of myofascial pain with ultrasonic therapy. J Prosthet Dent. 1984;51:106-108.
5. Carter JE. Surgical treatment for chronic pelvic pain. JSLS. 1998;2:129-139.
6. Meyer HP. Myofascial pain syndrome and its suggested role in the pathogenesis and treatment of fibromyalgia syndrome. Curr Pain Headache Rep. 2002;6:274-283.
7. Nicolakis P, Erdogmus B, Kopf A, et al. Effectiveness of exercise therapy in patients with myofascial pain dysfunction syndrome. J Oral Rehabil. 2002;29:362-368.
8. Baldry P. Management of myofascial trigger point pain. Acupunct Med. 2002;20:2-10.
9. Hambleton P. Clostridium botulinum toxins: A general review of involvement in disease, structure, mode of action and preparation for clinical use. J Neurol. 1992;239:16-20.
10. Royal MA, Gunyea I, Bhakta B, et al. Botulinum toxin type A in the treatment of refractory myofascial pain. Neurology. 2001;56(Suppl 3):A350. Abstract.
11. Hanson MA, Stevens RC. Structural view of botulinum neurotoxin in numerous functional states. In: Brin M, Hallett M, Jankovic J, eds. Scientific and Therapeutic Aspects of Botulinum Toxin. Philadelphia: Lippincott Williams and Wilkins; 2002:11-27.
12. Cui M, Khanijou S, Rubino J, Aoki KR. Botulinum toxin A inhibits the inflammatory pain in the rat formalin model. SFN Abstracts. 2000;26:656. Abstract.
13. Ishikawa H, Mitsui Y, Yoshitomi T, et al. Presynaptic effects of botulinum toxin type A on the neuronally evoked response of albino and pigmented rabbit iris sphincter and dilator muscles. Jpn J Ophthalmol. 2000;44:106-109.
14. Borodic GE, Acquadro M, Johnson EA. Botulinum toxin therapy for pain and inflammatory disorders: Mechanisms and therapeutic effects. Expert Opin Investig Drugs. 2001;10:1531-1544.
15. Lew MF, Adornato BT, Duane DD, et al. Botulinum toxin type B: A double-blind, placebo-controlled, safety and efficacy study in cervical dystonia. Neurology. 1997;49:701-707.
16. Brashear A, Lew MF, Dykstra DD, et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia. Neurology. 1999;53:1439-1446.
17. Brin MF, Lef MF, Adler CH, et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia. Neurology. 1999;53:1431-1438.
18. Dressler D, Benecke R. Initial experiences with clinical use of botulinum toxin type B [in German]. Nervenarzt. 2002;73:194-198.
19. Botox [package insert]. Irvine, Calif: Allergan, Inc; 2000.
20. Myobloc [package insert]. San Diego, Calif: Elan Biopharmaceuticals, Inc; 2000.
21. Lang AM. A pilot study of botulinum toxin type A (BOTOX®), administered using a novel injection technique, for the treatment of myofascial pain. Am J Pain Manag. 2000;10:108-112.
22. Cheshire WP, Abashian SW, Mann JD. Botulinum toxin in the treatment of myofascial pain syndrome. Pain. 1994;59:65-69.
23. Alo K, Yland MJ, Kramer DL, et al. Botulinum toxin in the treatment of myofascial pain. Pain Clin. 1997;10:107-116.
24. Wheeler AH, Goolkasian P, Gretz SS. A randomized, double-blind, prospective pilot study of botulinum toxin injection for refractory, unilateral, cervicothoracic, paraspinal, myofascial pain syndrome. Spine. 1998;23:1662-1666.
25. Wheeler AH, Goolkasian P. Open label assessment of botulinum toxin A for pain treatment in a private outpatient setting. J Musculoskelet Pain. 2001;9:67-82.
26. Foran PG, Mohammed N, Lisk GO, et al. Evaluation of the therapeutic usefulness of botulinum neurotoxin B, Cl, E, and F compared to the long lasting type A. Basis for distinct durations of inhibition of exocytosis in central neurons. J Biol Chem. 2003;278:1363-1371.
27. Roger Aoki K. Botulinum neurotoxin serotypes A and B preparations have different safety margins in preclinical models of muscle weakening efficacy and systemic safety. Toxicon. 2002;40:923-928.
28. Lowe NJ, Yamauchi PS, Lask GP, et al. Botulinum toxins types A and B for brow furrows: Preliminary experiences with type B toxin dosing. J Cosmet Laser Ther. 2002;4:15-18.